1-10 of 10
Maximilian F. Stahl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review

Adi Sherban, Danielle Fredman, Shai Shimony, Moshe Yeshurun, Pia Raanani, Maximilian F. Stahl, Anat Gafter-Gvili, Ofir Wolach
Journal: Blood
Blood (2022) 140 (Supplement 1): 11716–11717.
https://doi.org/10.1182/blood-2022-163152
Published: 2022
Journal Articles

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 319–321.
https://doi.org/10.1182/blood-2022-158465
Published: 2022
Journal Articles

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, Daniel J. DeAngelo
Journal: Blood
Blood (2022) 140 (Supplement 1): 6285–6287.
https://doi.org/10.1182/blood-2022-170587
Published: 2022
Journal Articles

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Jan Philipp Bewersdorf, Maximilian F. Stahl, Justin Taylor, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Victoria Kostantakis, Sydney X. Lu, Jessie Bourcier, Simon Hogg, Tulasigeri M Totiger, Omar Abdel-Wahab, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 9065–9067.
https://doi.org/10.1182/blood-2022-156830
Published: 2022
Journal Articles

Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)

Maximilian F. Stahl, Gerard Giblin, Yiwen Liu, Daniel J DeAngelo, Richard M. Stone, Eric S. Winer, Martha Wadleigh, Coleman Lindsley, Shai Shimony, Kevin Copson, Anne Charles, Anju Nohria, Marlise R. Luskin
Journal: Blood
Blood (2022) 140 (Supplement 1): 6067–6068.
https://doi.org/10.1182/blood-2022-159193
Published: 2022
Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 6058–6060.
https://doi.org/10.1182/blood-2022-163795
Published: 2022
Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 1435–1437.
https://doi.org/10.1182/blood-2022-167731
Published: 2022
Journal Articles

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Shai Shimony, Geoffrey G Fell, Evan C. Chen, Harrison Tsai, Martha Wadleigh, Eric S. Winer, Jacqueline S. Garcia, Marlise R. Luskin, Maximilian F. Stahl, Donna S. Neuberg, Daniel J DeAngelo, R. Coleman Lindsley, Richard M. Stone
Journal: Blood
Blood (2022) 140 (Supplement 1): 8938–8939.
https://doi.org/10.1182/blood-2022-162716
Published: 2022
Journal Articles

International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis

Jan Philipp Bewersdorf, Alyssa Grimshaw, Uwe Platzbecker, Pierre Fenaux, Mikkael A. Sekeres, Amer M. Zeidan, Maximilian F. Stahl
Journal: Blood
Blood (2022) 140 (Supplement 1): 9811–9812.
https://doi.org/10.1182/blood-2022-158622
Published: 2022
Journal Articles

Mutant Srsf2 Diminishes Jak2 V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2 -Mutant MPN

Anna E Marneth, Jonas S. Jutzi, Chulwoo J. Kim, Charles Laurore, Anastasia Tishena, Frederike Kramer, Azucena V. Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian F. Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Timothy A. Graubert, Ann Mullally
Journal: Blood
Blood (2022) 140 (Supplement 1): 1089–1090.
https://doi.org/10.1182/blood-2022-158823
Published: 2022